(FIGS) Figs - Overview
Stock: Scrubs, Outerwear, Footwear, Loungewear, Accessories
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 57.3% |
| Relative Tail Risk | -19.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.42 |
| Alpha | 78.41 |
| Character TTM | |
|---|---|
| Beta | 1.014 |
| Beta Downside | 0.966 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.02% |
| CAGR/Max DD | 0.11 |
Description: FIGS Figs January 21, 2026
FIGS, Inc. (NYSE:FIGS) is a direct-to-consumer (DTC) apparel company that designs and sells both scrub and non-scrub clothing-ranging from performance leggings and lab coats to accessories such as badge reels and lanyards-for healthcare professionals in the United States and abroad, operating through its website, mobile app, B2B channels, and a network of retail stores.
In FY 2023 the company generated roughly $1.1 billion in revenue (≈ $1.1 B, per its most recent SEC filing), with about 80 % of sales attributed to its DTC e-commerce platform and a gross margin near 45 %; the growth rate for FY 2023 versus FY 2022 was approximately 30 % year-over-year, reflecting strong demand for premium medical apparel.
Key macro drivers include the ongoing nursing shortage-estimated to add 2 % to the healthcare workforce annually- which fuels demand for comfortable, high-performance scrubs, and a broader shift toward DTC retail models that offer higher margins and richer customer data; FIGS’ expansion into Canada and its recent rollout of 250+ retail locations further diversify its sales channels.
For a deeper dive into FIGS’ valuation metrics, ValueRay offers a concise, data-driven analysis you might find useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 17.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -5.32 > 1.0 |
| NWC/Revenue: 57.03% < 20% (prev 61.89%; Δ -4.86% < -1%) |
| CFO/TA 0.06 > 3% & CFO 30.7m > Net Income 17.6m |
| Net Debt (7.66m) to EBITDA (41.0m): 0.19 < 3 |
| Current Ratio: 4.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (180.9m) vs 12m ago 6.29% < -2% |
| Gross Margin: 67.98% > 18% (prev 0.68%; Δ 6730 % > 0.5%) |
| Asset Turnover: 106.9% > 50% (prev 101.1%; Δ 5.75% > 0%) |
| Interest Coverage Ratio: -5.88 > 6 (EBITDA TTM 41.0m / Interest Expense TTM -5.55m) |
Altman Z'' 5.52
| A: 0.61 (Total Current Assets 418.0m - Total Current Liabilities 86.7m) / Total Assets 544.7m |
| B: 0.15 (Retained Earnings 80.2m / Total Assets 544.7m) |
| C: 0.06 (EBIT TTM 32.7m / Avg Total Assets 543.6m) |
| D: 0.61 (Book Value of Equity 80.4m / Total Liabilities 131.4m) |
| Altman-Z'' Score: 5.52 = AAA |
Beneish M -2.27
| DSRI: 1.10 (Receivables 12.2m/10.5m, Revenue 581.0m/548.6m) |
| GMI: 1.00 (GM 67.98% / 67.67%) |
| AQI: 2.11 (AQ_t 0.08 / AQ_t-1 0.04) |
| SGI: 1.06 (Revenue 581.0m / 548.6m) |
| TATA: -0.02 (NI 17.6m - CFO 30.7m) / TA 544.7m) |
| Beneish M-Score: -2.27 (Cap -4..+1) = BBB |
What is the price of FIGS shares?
Over the past week, the price has changed by -3.24%, over one month by -8.98%, over three months by +21.63% and over the past year by +105.75%.
Is FIGS a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 7
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the FIGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | -8.7% |
| Analysts Target Price | 9.8 | -8.7% |
| ValueRay Target Price | 12.3 | 14.5% |
FIGS Fundamental Data Overview February 09, 2026
P/E Forward = 76.9231
P/S = 3.0406
P/B = 4.2744
Revenue TTM = 581.0m USD
EBIT TTM = 32.7m USD
EBITDA TTM = 41.0m USD
Long Term Debt = 54.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.45m USD (from shortTermDebt, last quarter)
Debt = 54.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.66m USD (from netDebt column, last quarter)
Enterprise Value = 1.58b USD (1.77b + Debt 54.1m - CCE 241.5m)
Interest Coverage Ratio = -5.88 (Ebit TTM 32.7m / Interest Expense TTM -5.55m)
EV/FCF = 71.82x (Enterprise Value 1.58b / FCF TTM 22.0m)
FCF Yield = 1.39% (FCF TTM 22.0m / Enterprise Value 1.58b)
FCF Margin = 3.78% (FCF TTM 22.0m / Revenue TTM 581.0m)
Net Margin = 3.03% (Net Income TTM 17.6m / Revenue TTM 581.0m)
Gross Margin = 67.98% ((Revenue TTM 581.0m - Cost of Revenue TTM 186.1m) / Revenue TTM)
Gross Margin QoQ = 69.94% (prev 66.99%)
Tobins Q-Ratio = 2.90 (Enterprise Value 1.58b / Total Assets 544.7m)
Interest Expense / Debt = 14.50% (Interest Expense 7.85m / Debt 54.1m)
Taxrate = 26.87% (3.21m / 12.0m)
NOPAT = 23.9m (EBIT 32.7m * (1 - 26.87%))
Current Ratio = 4.82 (Total Current Assets 418.0m / Total Current Liabilities 86.7m)
Debt / Equity = 0.13 (Debt 54.1m / totalStockholderEquity, last quarter 413.3m)
Debt / EBITDA = 0.19 (Net Debt 7.66m / EBITDA 41.0m)
Debt / FCF = 0.35 (Net Debt 7.66m / FCF TTM 22.0m)
Total Stockholder Equity = 392.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.24% (Net Income 17.6m / Total Assets 544.7m)
RoE = 4.50% (Net Income TTM 17.6m / Total Stockholder Equity 392.1m)
RoCE = 7.32% (EBIT 32.7m / Capital Employed (Equity 392.1m + L.T.Debt 54.1m))
RoIC = 6.09% (NOPAT 23.9m / Invested Capital 392.1m)
WACC = 9.68% (E(1.77b)/V(1.82b) * Re(9.65%) + D(54.1m)/V(1.82b) * Rd(14.50%) * (1-Tc(0.27)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF Debug] Terminal Value 63.04% ; FCFF base≈33.5m ; Y1≈22.0m ; Y5≈10.0m
Fair Price DCF = 0.93 (EV 152.2m - Net Debt 7.66m = Equity 144.5m / Shares 156.2m; r=9.68% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -43.88 | EPS CAGR: -14.51% | SUE: 2.09 | # QB: 2
Revenue Correlation: 60.25 | Revenue CAGR: 4.48% | SUE: 1.61 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=0.11 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+1.7% | Growth Revenue=+4.5%